New REference: Talazoparib and Enzalutamide for HRR-Deficient Prostate Cancer

  • Study

    Randomised, placebo-controlled, phase 3 trial [TALAPRO-2]
    Metastatic castration-resistant prostate cancer with HRR-deficiency
    Talazoparib+enzalutamide (n=200) vs enzalutamide+placebo (n=199)

  • Efficacy

    ORR: 69% vs 38%
    mOS: 45.1 mos vs 31.1 mos (HR 0.62 [0.48-0.81])
    BRCA1/2 population: mOS not reached vs 28.5 mos (HR 0.50 [0.32-0.78])
    mPFS: 30.7 mos vs 12.3 mos (HR 0.47 [0.36-0.61])

  • Safety

    Grade >=3 AEs: anaemia (43% vs 5%), neutropenia (20% vs 1%)


    • Lancet Oncol 2025. Published online July 16, 2025

    Fizazi K,Azad AA,Matsubara N Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial

    http://doi.org/10.1016/S0140-6736(25)00683-X

    Reviewed by Elvin Chalabiyev, MD on Sep 3, 2025

    Altai Oncology App
    Download Altai Oncology App On App Store
    Download Altai Oncology App On Play Store
    • Chemotherapy Protocols
    • Summarized References
    • Oncology Drug Specs
    • TNM Staging
    • BSA, CrCl Calculator
    Back to top Drag